Q32 Bio Inc. (DB0.F)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Ms. Jodie Pope Morrison | CEO & Director | 749.86k | -- | 1976 |
| Dr. Shelia M. Violette Ph.D. | Co-founder, Chief Scientific Officer & President of Research | 545.2k | -- | 1961 |
| Dr. Jason A. Campagna M.D., Ph.D. | Chief Medical Officer | 598.85k | -- | 1967 |
| Mr. Lee H. Kalowski M.B.A. | CFO & President | -- | -- | 1981 |
| Dr. Saul W. Fink Ph.D. | Chief Technology Officer | -- | -- | -- |
| Mr. David Appugliese J.D. | Senior VP & Head of People | -- | -- | -- |
| Ms. Maria Marzilli M.P.H. | Executive Vice President of Corporate Strategy & Program Operations | -- | -- | -- |
| Ms. Kathryn E. Golden M.B.A. | Head of Chemistry, Manufacturing & Controls | -- | -- | -- |
Q32 Bio Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 42
Description
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition. The company was founded in 2017 and is based in Waltham, Massachusetts.
Corporate Governance
Upcoming Events
May 7, 2025 at 12:30 PM UTC - May 12, 2025 at 12:30 PM UTC
Q32 Bio Inc. Earnings Date
Recent Events
Recent Events Information Not Available